| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/23/2003 | US20030018194 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents |
| 01/23/2003 | US20030018193 Beta-alanine derivatives and their use as receptor anatgonists |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018085 Isostearic acid salts as permeation enhancers |
| 01/23/2003 | US20030018083 Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine |
| 01/23/2003 | US20030018079 Treatment |
| 01/23/2003 | US20030018078 Glaucoma treatments with reduced hyperpigmentation |
| 01/23/2003 | US20030018077 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018064 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 01/23/2003 | US20030018060 Therapeutic methods and compositions involving isoflavones |
| 01/23/2003 | US20030018056 Sodium channel moderators; cardiovascular disorders; antidiabetic agents |
| 01/23/2003 | US20030018041 Spiroindene and spiroindane compounds |
| 01/23/2003 | US20030018040 Tumor necrosis factor antagonist; side effect reduction;antiinflammatory agents |
| 01/23/2003 | US20030018038 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| 01/23/2003 | US20030018035 Central nervous system disorders |
| 01/23/2003 | US20030018026 Preterm labor; urogenital disorders; fertility; psychological disorders |
| 01/23/2003 | US20030018021 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists |
| 01/23/2003 | US20030018013 Cardiovascular disorders; antilipemic agents; Alzheimer's disease |
| 01/23/2003 | US20030018007 Compositions and methods for inducing gene expression |
| 01/23/2003 | US20030017989 Use of angiotensin I derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| 01/23/2003 | US20030017988 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 01/23/2003 | US20030017564 Tryptophanyl-tRNA synthetase derived polypeptides useful for the regulation of angiogenesis |
| 01/23/2003 | US20030017562 Nucleotide sequences coding polypetide for use in the treatment, prevention and diagnosis of gastrointestinal and apoptosis disorders |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017512 Angiostatin receptor |
| 01/23/2003 | US20030017510 Apparatus for use in cell transplantation |
| 01/23/2003 | US20030017166 Combination preparation for the therapy of immunological diseases |
| 01/23/2003 | US20030017164 Dye-azide compounds for dual phototherapy |
| 01/23/2003 | US20030017157 Endothelial cell expression patterns |
| 01/23/2003 | US20030017147 Novel alpha-2-antiplasmin- binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient |
| 01/23/2003 | US20030017145 Treating subjects suffering from herpes virus infections, acquired immunodeficiency syndrome, and hepatitis C infections by administering a compound effective to inhibit the production or release of the ROMs. |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | CA2821544A1 Use of follistatin for the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease |
| 01/23/2003 | CA2707767A1 Biologically active peptides |
| 01/23/2003 | CA2453566A1 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | CA2453470A1 Use of follistatin for the treatment of hepatic fibrogenesis |
| 01/23/2003 | CA2453451A1 Aminediols for the treatment of alzheimer's disease |
| 01/23/2003 | CA2453444A1 Diaminediols for the treatment of alzheimer's disease |
| 01/23/2003 | CA2453438A1 Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453285A1 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 01/23/2003 | CA2453216A1 Amphiphilic star-like macromolecules for drug delivery |
| 01/23/2003 | CA2453183A1 In vivo production of small interfering rnas that mediate gene silencing |
| 01/23/2003 | CA2453147A1 Methods of treating cytokine mediated diseases |
| 01/23/2003 | CA2452544A1 Method for treating secondary tissue degeneration associated with central nervous system injury |
| 01/23/2003 | CA2452417A1 Compositions comprising the biologicially active peptide ysl |
| 01/23/2003 | CA2451569A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | CA2448553A1 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | CA2446726A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | CA2422349A1 Process for purifying n2-(1(s)-ethoxycarbonyl-3-phenylpropyl)-n6-trifluoroacetyl-l-lysine |
| 01/23/2003 | CA2418173A1 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 01/22/2003 | EP1277760A1 Method of searching for arteriosclerosis inhibitors and shrinkers |
| 01/22/2003 | EP1277746A2 N-benzylpiperazine derivatives, process for their preparation and pharmaceutical compositions thereof |
| 01/22/2003 | EP1277743A1 Oxa(thia)zolidine derivative and anti-inflammatory drug |
| 01/22/2003 | EP1277730A1 Neovascularization inhibitors |
| 01/22/2003 | EP1277729A1 Ppar (gamma) modulators |
| 01/22/2003 | EP1277470A1 Injectable galenical formulation for use in photodynamic diagnostic or therapy and process of manufacturing it |
| 01/22/2003 | EP1276893A1 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 01/22/2003 | EP1276880A2 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 01/22/2003 | EP1276878A2 Reversible immortalization |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276761A2 New bromodomain protein |
| 01/22/2003 | EP1276755A1 Novel compounds |
| 01/22/2003 | EP1276739A2 Heterocycles that are inhibitors of impdh enzyme |
| 01/22/2003 | EP1276738A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/22/2003 | EP1276737A1 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) |
| 01/22/2003 | EP1276731A2 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht 1a activity |
| 01/22/2003 | EP1276730A2 Thiazolidinedione analogues and their use for the treatment of diabetes |
| 01/22/2003 | EP1276729A1 New neurokinin antagonists for use as medicaments |
| 01/22/2003 | EP1276725A2 5-substituted tetralones as inhibitors of ras farnesyl transferase |
| 01/22/2003 | EP1276724A2 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase |
| 01/22/2003 | EP1276722A1 Naphthamidine urokinase inhibitors |
| 01/22/2003 | EP1276714A2 Cyclic carboxylic acids as integrin antagonists |
| 01/22/2003 | EP1276491A1 Tamandarin and didemnin analogs and methods of making and using them |
| 01/22/2003 | EP1276483A2 Compositions and methods for treating amyloidosis using sulphonate derivatives |
| 01/22/2003 | EP1276476A2 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
| 01/22/2003 | EP1276462A2 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | EP1079834B1 Stable compositions comprising levosimendan and alginic acid |
| 01/22/2003 | EP1030835B1 Urea derivatives and their use as integrin inhibitors |
| 01/22/2003 | EP0973774B1 1,5-dihydro-pyrazolo 3,4-d]-pyrimidinone derivatives |
| 01/22/2003 | EP0937085B1 Magnesium (-)hydroxycitrate, method of preparation, applications, and compositions in particular pharmaceutical containing same |
| 01/22/2003 | EP0728009B1 Use of an agent which modulates tyrosine phosphorylation for modulating the permeability of a psychological barrier |
| 01/22/2003 | CN1392874A Cyclic amidine compounds |
| 01/22/2003 | CN1392254A Recombined adenovirus and its use in curing myocardial ischemia |
| 01/22/2003 | CN1391945A Xuemaitong medicine for promoting blood circulation and its producing method |
| 01/22/2003 | CN1391936A Chinese medicine for curing internal and external piles and preparing method |
| 01/22/2003 | CN1391922A Medicine for curing paralysis |
| 01/22/2003 | CN1391915A Chouxue qing capsule for reducing blood viscosity |
| 01/22/2003 | CN1391912A Kidney invigorating and bone strengthening medicine and its preparing method |
| 01/22/2003 | CN1391899A Aseptic freeze-dried prostaglandin injection and its preparing method and use |
| 01/22/2003 | CN1391897A Flunarizine hydro-chloride capsule pill |
| 01/22/2003 | CN1391893A Process for preparing simvastation drip pill |
| 01/22/2003 | CN1099462C Medical composition |
| 01/21/2003 | US6509499 Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment |
| 01/21/2003 | US6509443 Amino acid residue located at position 63 of native-sequence human Insulin like Growth Factor-I is replaced with an alanine residue or amino acid residues at positions 1 and 70 are replaced with serine and valine respectively |